Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

Study Overview
=================
Brief Summary
-----------------
The overall purpose of this study is to characterize the effect of probiotics on the oral microbiota in older adults with dysphagia at risk for pneumonia.

Detailed Description
-----------------
The goal of this pilot study is to characterize the effects of probiotics on the oral microbiota in older patients with dysphagia at risk for pneumonia. A total of 20 participants will be recruited from the UW Health Inpatient Swallowing Consult Service. Participants will have a dysphagia diagnosis along with documented aspiration on videofluoroscopy. Each participant will receive a once daily VSL#3 probiotic blend (dissolved in thickened liquid as applicable) for 28 days. A baseline assessment will be completed to collect data on demographics, health history and behaviors, usual diet, level of oral intake, and patient-reported swallow function. Oral swab (buccal mucosa and tongue dorsum) as well as saliva sample collections will be completed. Data on adherence and adverse events will be collected weekly. Bacterial DNA will be extracted from oral samples and 16S rRNA sequencing techniques will be used to identify contents of oral microbiota at baseline, week 2, and week 4. Oral microbial composition will be compared between the time points, and treatment feasibility (recruitment and retention rates) in this population will be evaluated.

Official Title
-----------------
Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia at Risk for Pneumonia

Conditions
-----------------
Dysphagia

Intervention / Treatment
-----------------
* Drug: VSL#3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria 65 years of age or older Dysphagia diagnosis based on videofluoroscopic swallow study with observed airway invasion (Penetration-Aspiration Scale score of 3 or higher) Ability to provide consent Ability to submit oral samples Ability to swallow sachet of probiotic (dissolved in thickened liquid, as needed) Ability to return to UWHC for week 2 and week 4 visits. Exclusion Criteria Currently taking antibiotics or probiotics Actively receiving immunosuppressive therapy Non-oral feeding with inability to swallow probiotic diagnosis of head and neck cancer or upper airway disease prior surgery to the head and neck region that would have affected the muscles of swallowing or the salivary glands history of chemotherapy or radiation to the head and neck region severe periodontal disease. currently pregnant or planning to become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Probiotic<br>The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow. | Drug: VSL#3<br>* Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.<br>* Other names: probiotic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Oral microbiota profiles- bacterial diversity | Next generation sequencing will be used to quantify the amount of alpha and beta diversity in samples collected from various locations in the oral cavity (buccal mucosa, dorsum of the tongue, saliva). | Baseline visit, 2 weeks post-enrollment, and 4 weeks post-enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eating Assessment Test (EAT-10) | Patient reported outcome measure for swallowing | Baseline visit | 
| Functional Oral Intake Scale (FOIS) Score | Scale used to quantify the amount of oral versus non-oral intake | Baseline visit | 
| Kayser-Jones Brief Oral Health Status Examination (BOHSE) | A valid and reliable scoring instrument developed for use with older adults by non-dental health care providers. | Baseline visit | 
| Change in Resting Swallow Frequency Rate | We will measure resting swallow frequency using surface electromyography (sEMG). | Baseline visit, 2 weeks post-enrollment, and 4 weeks post-enrollment | 
| Change in Residual Mucosal Saliva (RMS) | Residual Mucosal Saliva will be collected from the anterior hard palate (AHP), buccal (BUC), anterior tongue (AT), and lower labial (LL) surfaces using SialoPaper strips | Baseline visit, 2 weeks post-enrollment, and 4 weeks post-enrollment | 
| Change in Amount of Saliva Produced | Salivary flow rate (ml/minute) will be calculated under unstimulated and stimulated saliva collection conditions. | Baseline visit, 2 weeks post-enrollment, and 4 weeks post-enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
probiotics, oral microbiome, dysphagia